MSLE Stock — Satellos Bioscience Inc. Common Stock

Satellos Bioscience Inc. Common Stock (MSLE)

Updated October 16, 2026.

MSLE is a Stock. Total return is -93.1% over the past 14.2 years, 693.2 points behind SPY at 600.1%.

Satellos Bioscience is a clinical-stage drug development company focused on treatments for degenerative muscle diseases, including its lead candidate SAT-3247 for Duchenne muscular dystrophy, utilizing its proprietary MyoReGenX discovery platform. The company does not currently distribute to shareholders. Satellos appeals to investors seeking exposure to early-stage biotechnology development with no current income component.

MSLE performance versus SPY

Price and return data through 2026-10-16.

Total return is -93.1% over the past 14.2 years, 693.2 points behind SPY at 600.1%. Over the past year its total return — price change plus distributions reinvested — is -5.6%. Its deepest 1-year drawdown was 57.0%.

MSLE key facts

Asset type

Stock

Asset class

Equity

Inception date

08/03/2012

Distribution frequency

None

Last close

$6.46 (as of 2026-10-16)

Market cap

$137,058,196

Average volume

13320.0

Beta

1.145

Payout ratio

0.0%

EPS

$-2.00

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MSLE risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 57.0%.

Who may consider MSLE — and who may not

It is a weaker fit for investors who need monthly cash flow (MSLE does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on MSLE

• All tickers starting with M

Tagged: Healthcare.

Frequently asked questions